Close the collaboration and license agreement with Novartis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- 26 Feb 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the transaction is expected to close in the first quarter of 2021, subject to expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.”
What we found
Evidence strength A What the grades mean
BeiGene successfully closed the collaboration and license agreement with Novartis on February 26, 2021, which falls within the first quarter of 2021.
-
A BeiGene, Ltd. 10-Q filed 2021-05-06
“On February 26, 2021, we announced the closing of the collaboration and license agreement with Novartis Pharma AG ("Novartis"), previously announced on January 11, 2021” ✓ confirmed on the page
Market reaction: the shares moved -1.2% against the S&P 500 over the three sessions around the disclosure (5 May 2021 to 10 May 2021). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Transaction other
- Indicative materiality
- Medium rules
- Action
- Close
- Deliverable
- collaboration and license agreement with Novartis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you BeiGene, Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ONC-022619 · Corrections policy